Immunoprecise Antibodies LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
ImmunoPrecise Antibodies achieved record revenue and improved gross margins in fiscal year 2025, driven by its BioStrand AI segment, but continues to face significant net losses, liquidity challenges, and substantial intangible asset impairments.
ImmunoPrecise Antibodies Ltd. has filed an amendment to its annual report on Form 20-F to correct a typographical error regarding the fiscal period.
20-F: ImmunoPrecise Antibodies Ltd. Files 20-F, Reports Record Revenue and Highlights AI Advancements
ImmunoPrecise Antibodies Ltd. files its 20-F, reporting record revenue of $24.5 million for fiscal year 2024 and highlighting technological advancements in its AI-driven platforms.